Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6621905 | 1.00 | SLC2A1 (0.49) | SLC2A1HTR2CCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6624636 | 1.00 | SLC2A1 (0.49) | SLC2A1HTR2CCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6621339 | 0.90 | SLC2A1 (0.51) | SLC2A1HTR2CCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6619597 | 0.88 | SLC2A1 (0.49) | SLC2A1HTR2CCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6620231 | 0.86 | SLC2A1 (0.48) | SLC2A1HTR2CCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6619627 | 0.86 | SLC2A1 (0.48) | SLC2A1HTR2CCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6623020 | 0.86 | SLC2A1 (0.48) | SLC2A1HTR2CCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6618765 | 0.84 | SLC2A1 (0.45) | SLC2A1HTR2CCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6618497 | 0.82 | SLC2A1 (0.46) | SLC2A1HTR2CCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6620299 | 0.81 | CHRNB2 (0.44) | SLC2A1CHRNB2CHRNA7CHRNA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818655-B2 | 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | claimed |
| EP-1359915-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040063757-A1 | Urotensin-ll receptor antagonists | SMITHKLINEE BEECHAM CORPORATION | 2004-04-01 | — | — | US | claimed |
| EP-1359915-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | Smithkline Beecham (US) | 2003-11-12 | — | — | EP | claimed |
| WO-2002058702-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-08-01 | — | — | WO | claimed |
| US-6818655-B2 | 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| EP-1359915-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040063757-A1 | Urotensin-ll receptor antagonists | SMITHKLINEE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-1359915-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | Smithkline Beecham (US) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002058702-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063757-A1 | Urotensin-ll receptor antagonists | UTS2R, PLAUR, SCTR | SLC2A1 3284/4885HTR2C 437/4885CHRNB2 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.